PE20070232A1 - Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina - Google Patents

Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina

Info

Publication number
PE20070232A1
PE20070232A1 PE2006000965A PE2006000965A PE20070232A1 PE 20070232 A1 PE20070232 A1 PE 20070232A1 PE 2006000965 A PE2006000965 A PE 2006000965A PE 2006000965 A PE2006000965 A PE 2006000965A PE 20070232 A1 PE20070232 A1 PE 20070232A1
Authority
PE
Peru
Prior art keywords
terbutoxi
campotecin
microparticles
imino
methyl
Prior art date
Application number
PE2006000965A
Other languages
English (en)
Inventor
Isabel Ottinger
Oskar Kalb
Agnes Taillardt
Wolfgang Wirth
Walter Stebler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070232A1 publication Critical patent/PE20070232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE; A) MICROPARTICULAS DE 7-TERBUTOXI-IMINO-METIL-CAMPOTECINA, EL CUAL ES UN INHIBIDOR DE LA TOPOISOMERASA I, EN UN TAMANO DE HASTA APROXIMADAMENTE 15 MICRAS, Y B) UN VEHICULO SELECCIONADO DE UN COMPUESTO: i) OLEOSO SELECCIONADO DE ACEITE DE MAIZ, DE AJONJOLI, OLIVO ENTRE OTROS; ii) NO ACUOSO HIDROFILICO SELECCIONADO DE ESTERES DE ACIDOS GRASOS DE 6 A 10 CARBONOS DE POLIETILENGLICOL-GLICERILO, ENTRE OTROS ; Y iii) AUTO-MICRO-EMULSIONANTE QUE COMPRENDE UNO O MAS COMPONENTES LIPOFILICOS, TENSIOACTIVOS Y OPCIONALMENTE HIDROFILICOS. ADEMAS PUEDE COMPRENDER UN INHIBIDOR DDE SEDIMENTACION TAL COMO SILICE COLOIDAL. ESTA COMPOSICION ES UTIL PARA EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES PROLIFERATIVAS, INCLUYENDO CANCER
PE2006000965A 2005-08-10 2006-08-08 Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina PE20070232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
PE20070232A1 true PE20070232A1 (es) 2007-04-09

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000965A PE20070232A1 (es) 2005-08-10 2006-08-08 Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina

Country Status (20)

Country Link
EP (1) EP1915132A1 (es)
JP (1) JP2009504616A (es)
KR (1) KR20080034989A (es)
CN (1) CN101287448A (es)
AR (1) AR055602A1 (es)
AU (1) AU2006277879A1 (es)
BR (1) BRPI0614757A2 (es)
CA (1) CA2618084A1 (es)
EC (1) ECSP088166A (es)
GT (1) GT200600364A (es)
IL (1) IL189076A0 (es)
MA (1) MA29735B1 (es)
MX (1) MX2008001965A (es)
NO (1) NO20081213L (es)
PE (1) PE20070232A1 (es)
RU (1) RU2008108885A (es)
TN (1) TNSN08062A1 (es)
TW (1) TW200800195A (es)
WO (1) WO2007017514A1 (es)
ZA (1) ZA200800726B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
GT200600364A (es) 2007-03-19
WO2007017514A1 (en) 2007-02-15
ZA200800726B (en) 2009-08-26
AU2006277879A1 (en) 2007-02-15
TNSN08062A1 (en) 2009-07-14
ECSP088166A (es) 2008-03-26
CN101287448A (zh) 2008-10-15
BRPI0614757A2 (pt) 2011-04-12
KR20080034989A (ko) 2008-04-22
JP2009504616A (ja) 2009-02-05
MA29735B1 (fr) 2008-09-01
AR055602A1 (es) 2007-08-29
EP1915132A1 (en) 2008-04-30
MX2008001965A (es) 2008-03-26
TW200800195A (en) 2008-01-01
RU2008108885A (ru) 2009-09-20
NO20081213L (no) 2008-05-13
IL189076A0 (en) 2008-08-07
CA2618084A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
SV2008003071A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
WO2008116135A3 (en) Topical formulations having enhanced bioavailability
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CO6390043A2 (es) Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencílico
WO2009156484A3 (en) Organic compounds
PE20080523A1 (es) Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
EA200802364A1 (ru) Композиция для ухода за кожей и ее применение
WO2008014229A3 (en) Dimeric iap inhibitors
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2010002926A (es) Moduladores de tieno y furo-pirimidina del receptor h4 de histamina.
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
DOP2019000128A (es) Composición para el tratamiento y/o prevención de la enfermedad fúngica sigatoka negra en los cultivos de banana
GT200500310A (es) Compuestos organicos
WO2009108857A3 (en) Combination therapy for prostate cancer
CL2012000611A1 (es) Compuesto 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2- trifluoro-etoxi)-nicotinamida, util como agente que aumenta el colesterol hdl; proceso de obtencion del compuesto; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la aterosclerosis, dislipidemia, enfermedades cardiovasculares, entre otras.
PE20070232A1 (es) Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina
MX2019001838A (es) Metodos y composiciones para el tratamiento de verrugas.

Legal Events

Date Code Title Description
FC Refusal